PER 1.41% 7.0¢ percheron therapeutics limited

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-169

  1. 246 Posts.
    lightbulb Created with Sketch. 26
    https://www.linkedin.com/posts/parentprojectmd_pfizer-discontinues-development-of-investigational-activity-7224075311850688512-9KDd?

    "PPMD is disappointed to learn that Pfizer Inc. has officially discontinued development of the company’s investigational mini-dystrophin #genetherapy, fordadistrogene movaparvovec. With this termination, Pfizer is not currently active in the Duchenne treatment space, which is a devastating setback for our community."

    Luckily for Pfizer, there is a DMD drug developer looking to partner up at the moment...

    GLTAH
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.